| 000 | 01724 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250513151105.0 | ||
| 264 | 0 | _c19981117 | |
| 008 | 199811s 0 0 eng d | ||
| 022 | _a0169-5002 | ||
| 024 | 7 |
_a10.1016/s0169-5002(98)00025-7 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aIsokangas, O P | |
| 245 | 0 | 0 |
_aPaclitaxel (Taxol) and carboplatin followed by concomitant paclitaxel, cisplatin and radiotherapy for inoperable stage III NSCLC. _h[electronic resource] |
| 260 |
_bLung cancer (Amsterdam, Netherlands) _cMay 1998 |
||
| 300 |
_a127-33 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Phytogenic _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aCarboplatin _xadministration & dosage |
| 650 | 0 | 4 |
_aCarcinoma, Non-Small-Cell Lung _xdrug therapy |
| 650 | 0 | 4 |
_aCisplatin _xadministration & dosage |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 | _aConfidence Intervals |
| 650 | 0 | 4 | _aDose Fractionation, Radiation |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 |
_aPaclitaxel _xadministration & dosage |
| 650 | 0 | 4 | _aSurvival Rate |
| 700 | 1 | _aJoensuu, H | |
| 700 | 1 | _aHalme, M | |
| 700 | 1 | _aJekunen, A | |
| 700 | 1 | _aMattson, K | |
| 773 | 0 |
_tLung cancer (Amsterdam, Netherlands) _gvol. 20 _gno. 2 _gp. 127-33 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0169-5002(98)00025-7 _zAvailable from publisher's website |
| 999 |
_c9677115 _d9677115 |
||